Published in AIDS Weekly, November 16th, 2009
The research will evaluate the effects of ALKA-V6 on animal organisms, and will be highly replicated with the goal of moving knowledge about the compound toward eventual FDA approval.
Dr. Troy Chesnut, Managing Member of Orizon Research Institute, stated, "We are excited to move our research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.